Universitair Medisch Centrum Utrecht

Clinical trials here focus on female urogenital diseases and neoplasms, especially cervical cancer, ovarian cancer, endometrial cancer, and locally advanced vulvar carcinoma. The research is aimed at improving treatment strategies, preserving fertility when possible, and refining outcomes for patients with hard-to-treat gynecological cancers.

• Comparing treatment approaches for locally advanced vulvar carcinoma to find the most effective path to disease control
• Studying ovarian cancer therapies to improve progression-free survival in recurrent disease
• Evaluating fertility-sparing care in cervical cancer to balance cancer control with future family planning
• Testing personalized approaches for endometrial cancer to reduce recurrence risk after surgery

Much of the work at this hospital-based research site is centered on better tailoring care for women with cancer, while also exploring whether new combinations of treatment can improve long-term outcomes and quality of life.

This site is active in blood cancer research across hemic and lymphatic diseases and neoplasms, with trials in acute myeloid leukemia, myelodysplastic syndrome, diffuse large B-cell lymphoma, small lymphocytic lymphoma, and chronic lymphocytic leukemia. The main goal is to test newer treatment strategies that may improve survival and deepen remission in aggressive or relapsed blood cancers.

• Assessing new treatment combinations for acute myeloid leukemia and related myelodysplastic syndromes
• Studying immunotherapy-based approaches in high-risk lymphoma and relapsed or refractory leukemia
• Evaluating whether novel regimens can improve disease control in chronic lymphocytic leukemia and small lymphocytic lymphoma
• Exploring strategies to extend remission and reduce relapse in difficult-to-treat myeloid malignancies

The research portfolio at Universitair Medisch Centrum Utrecht reflects a strong interest in advancing precision treatment for hematologic cancers, especially where standard options are limited.

Another major area of research involves immune system diseases and chronic inflammatory conditions such as atopic dermatitis, chronic spontaneous urticaria, idiopathic inflammatory myopathies, systemic sclerosis, IgG4-related disease, and Behcet’s disease. These trials mainly aim to improve symptom control, long-term safety, and overall disease management.

• Testing new therapies for moderate-to-severe atopic dermatitis and chronic spontaneous urticaria
• Studying treatments for idiopathic inflammatory myopathies, systemic sclerosis, and other rare autoimmune diseases
• Evaluating whether newer immune-targeted medicines can better control inflammation and improve daily functioning
• Supporting drug repurposing efforts in rare immune-mediated inflammatory diseases

These studies highlight a broad effort to improve care for patients with complex inflammatory disorders, with attention to both effectiveness and tolerability over time.

The site also conducts trials in bacterial infections and mycoses, virus diseases, and respiratory tract diseases, including food allergy, peanut allergy, cystic fibrosis, hospital-acquired pneumonia, COVID-19, monkeypox, and Staphylococcus aureus bacteremia. The purpose is often to improve prevention, reduce complications, and test better treatment options for acute and chronic illness.

• Evaluating allergy-focused therapies for food allergy and peanut allergy
• Studying new approaches for cystic fibrosis and related lung complications
• Testing treatments for serious infections such as hospital-acquired pneumonia, Staphylococcus aureus bacteremia, and COVID-19
• Assessing interventions for emerging viral illness, including monkeypox

Research in this area combines prevention and treatment goals, with an emphasis on helping patients avoid severe infection-related complications and improve respiratory health.

Clinical trials in this area cover cardiovascular diseases, atherosclerosis, heart failure, atrial fibrillation, stroke prevention, hypertriglyceridemia, and familial hypercholesterolemia. The main aim is to improve risk reduction, prevent serious events, and evaluate the safety and effectiveness of newer therapies.

• Testing treatments for heart failure and cardiomyopathy to improve cardiac function and symptoms
• Studying medicines for stroke prevention in people with prior stroke, transient ischemic attack, or atrial fibrillation
• Evaluating therapies for high triglycerides and other metabolic lipid disorders
• Exploring new options for patients with atherosclerotic cardiovascular disease and inherited cholesterol disorders

This cardiovascular research at UMC Utrecht reflects a strong focus on lowering long-term risk while finding treatments that are both effective and safe for everyday clinical use.

Trials in nervous system diseases include amyotrophic lateral sclerosis, mild cognitive impairment and dementia, H3 K27M-mutant diffuse glioma, uveitic macular edema, and diagnostic work in carcinoma of unknown primary. This research aims to improve diagnosis, guide treatment decisions, and assess whether newer tools can better support patient care.

• Evaluating treatment options for diffuse glioma and other serious neurological conditions
• Studying tau PET and other imaging tools to improve diagnostic accuracy in cognitive disorders
• Assessing eye-related therapies for uveitic macular edema to protect vision
• Investigating whether advanced imaging can help identify the origin of carcinoma of unknown primary

These studies show a broad interest in better diagnosis and more precise treatment selection across neurological and related disorders.

The site also supports trials in congenital and hereditary diseases and nutritional and metabolic diseases, including osteogenesis imperfecta, methylmalonic acidemia, cystic fibrosis bronchiectasis, haemophilia A, and ATTR amyloidosis. The research focus is on long-term safety, disease control, and improving function in people living with rare conditions.

• Testing therapies for osteogenesis imperfecta to reduce fractures and improve mobility
• Evaluating treatment support for methylmalonic acidemia and other inherited metabolic disorders
• Studying new options for haemophilia A and related bleeding disorders
• Investigating therapies for ATTR amyloidosis and other rare protein-folding diseases

At Universitair Medisch Centrum Utrecht, these trials contribute to a growing effort to bring more targeted care to patients with rare and often lifelong conditions.